30 results about "Endothelial repair" patented technology

The invention relates to a preparation method of blood contact material for improving the biocompatibility and a blood contact material, and relates to the field of biomedical functional materials. The preparation method of the blood contact material for improving the biocompatibility is that the MES, the EDC, the NHS and the water are uniformly mixed and prepared into an activating agent; the base material with the amino-rich coating is immersed in the first mixed solution prepared by the hyaluronic acid solution and the activating agent to carry out the first amine reaction, then is taken out for cleaning with water for a plurality of times to obtain the HA-modified material; the HA-modified material is immersed in a second mixed solution prepared by the selenocysteamine solution and theactivating agent to carry out the second amine reaction, then is taken out for cleaning with water for multiple times, and the blood contact material is obtained. The preparation method can remarkably improve the biocompatibility of the material, so as to reduce the incidence of adverse reaction; the blood contact material has good anti-coagulation, smooth muscle hyperplasia, and endothelial repair function and biocompatibility.

The invention belongs to the technical field of medical apparatus and instruments, and specially relates to the technical field capable of performing damage endothelium repair on a device implantationposition. The invention provides an application of anti-adhesion polypeptide in preparation of an implanted medical instrument. The implanted medical device is loaded with a cell trapping substance and the anti-adhesion polypeptide. A preparation method of the implanted medical instrument includes the following steps: loading the cell trapping substance on a surface of the cell trapping substancethat the implanted medical device plan to load, and loading the anti-adhesion polypeptide into a hole or a groove of the implanted medical device. According to the technical scheme, from the perspective of anti-cell adhesion, a mechanism of combining the anti-adhesion peptide with an adhesion molecule on a cell membrane is adopted, and the adhesion of other types of cells except captured specialcells to the surface of the implanted medical device is blocked, and therefore, the purity of the captured cells can be greatly improved, the efficiency of endothelial repair is improved, thereby achieving the purpose of promoting endothelial neogenesis, inhibiting intimal hyperplasia, and inhibiting an inflammatory reaction.

The invention discloses a construction method of an enzyme-reponsive multifunctional nano-coating. The construction method comprises the following steps: firstly, immobilizing avidin molecules to the surface of dopamine-coated stainless steel; then, on the basis of specific recognition and binding effects between avidin and biotin, immobilizing biotinylated heparin/PEI nanoparticles to the surface of a material, and further binding high-concentration avidin molecules to residual biotin on the surface of a nanoparticle coating, so that a novel biotin binding site is introduced; then, continuing to assemble biotinylated enzyme-responsive polypeptide to the surfaces of the nanoparticles on the basis of an interaction between the biotin and the avidin; and finally, by virtue of an EDC/NHS/MES coupling agent, immobilizing SDF-1[alpha] to an amino terminal of the polypeptide in a covalent mode, so that the multifunctional nano-coating, which has a matrix metalloproteinase 9 responsive characteristic, is constructed. According to the construction method provided by the invention, by constructing a multifunctional layer, which has anti-coagulating and endothelial regeneration inducing capacities, on a titanium surface, blood compatibility and a damaged endothelial repair capacity of the material can be obviously improved.

The present invention relates to the field of medicine, in particular to a medical use of psoralenchalcone and its analogues, which are compounds with the structure of formula (I), or their pharmaceutical Acceptable salts, tautomers, stereoisomers or prodrugs above: Among them, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ each independently selected from the group consisting of hydrogen, ORa, OCOORa, OCONRaR _b 、OSO ₂ Ra and OSO ₃ Ra; the Ra and R _b each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted C6-C30 aryl group, and substituted or unsubstituted C1-C30 heteroaryl group; the psoralen chalcone and its analogues are used to prepare medicines or health care products for promoting vascular endothelial repair and/or angiogenesis.

A stent with multi drug-coatings includes a stent body and active drugs. A portion of the surface or the entire surface of the stent body is covered with at least one layer of active drug coating. Use of such a stent not only can accelerate endothelialization of coronary, but also resist cell proliferation, resist the migration of smooth muscle cells, reduce the formation of thrombus and the inflammatory reaction of cells and recover the flexibility of vascular tissues. Multi drug-coatings can prevent the multiple phases of restenosis, resist the release of drugs at different phases of endothelial repair, and play a role in co-resisting vessel stent restenosis by various drugs. Well-composed multi drug-coatings make the coating area and coating layers of drug-eluting stent and drugs compatibility more reasonable, make the use of drug-eluting stent more secure, and produce better treatment effects.

The present invention relates to the field of therapy and prophylaxis of vascular tissue damage and/or complications and/or disease of vascular tissue by vascular regeneration and endothelium repair. The inventors have found that administration of an androgen receptor agonist alleviates one or more adverse vascular diseases and/or vascular complications thereof or adverse effects of androgen deficiency, with implications for prophylactic and therapeutic interventions.

The invention belongs to the field of medical apparatuses, and in particular relates to a drug stent and a preparation method thereof. The drug stent comprises a stent main body and a pharmaceutical composition distributed on the surface of the stent main body, wherein the pharmaceutical composition consists of amlexanox, taxol, sirolimus and aspirin. The preparation method comprises the followingsteps: firstly, preparing mixed powder or a mixed solution of the pharmaceutical composition; and then, loading the medicine (the prepared mixed powder or the mixed solution) onto the surface of thestent main body in a dripping, land-filling or coating mode. According to the invention, the composition of the amlexanox, the taxol, the sirolimus and the aspirin is high in activity of inhibiting smooth muscle cell proliferation; the drug stent with the composition, in comparison with currently common drug eluting stents, also has the characteristic of being low in endothelial cell proliferationinhibiting performance; therefore, the drug stent can be used for preventing a vascular restenosis occurrence rate in a PTCA postoperative treatment process; and meanwhile, endothelial repair cannotbe delayed.

The invention belongs to application of a specific antibody, an implantable medical instrument and a preparation method. The application is the application of the specific antibody of a hematopoieticstem cell marker in preparing a medicine for promoting endothelial repair. The specific antibody of the hematopoietic stem cell marker is loaded on the surface of the implantable medical instrument. Apreparation method comprises: a step of loading the specific antibody of the hematopoietic stem cell marker on at least a part of the surface of the implantable medical instrument, and a step of loading the specific antibody of the hematopoietic stem cell marker in a hole or a groove of the implantable medical instrument. According to the technical scheme provided by the invention, the specific antibody of the hematopoietic stem cell marker is creatively used for realizing the effect of promoting endothelial repair of the medical instrument. Compared with an existing endothelial repair mode,the specific antibody captures hematopoietic stem cells of a human body and induces to generate cells to achieve targeted endothelial repair. The mode has small medicine side effect, no other adverseeffects and more ideal comprehensive curative effect.

The invention discloses a cardiovascular implant intervention material/instrument biological film coating and a preparation method thereof. The preparation method comprises the following steps: (1) preparing a cell membrane vesicle suspension; (2) constructing a super-hydrophilic coating on the surface of the substrate material; and (3) co-incubating the cell membrane vesicle suspension obtained in the step (1) and the super-hydrophilic coating obtained in the step (2), and cleaning with deionized water to obtain the cardiovascular implant intervention material/instrument biological membrane coating. The invention also comprises the cardiovascular implant intervention material/instrument biological film coating prepared by the method. According to the coating, the surface of a large-scale medical device is coated with a cell membrane for the first time, the anticoagulation performance and the anti-inflammatory performance of a blood contact material can be effectively enhanced, and the coating has the capacity of promoting endothelial repair and can be suitable for modification of medical interventional devices such as heart occluders, heart valves, intravascular stents and artificial blood vessels; the inflammatory reaction degree and the thrombosis risk after the instrument is implanted can be obviously reduced.

The invention provides an application of a Notch signaling pathway in inhibition of PCI postoperative restenosis by ACE2, in-vivo research is carried out by establishing a model of rat balloon injury aortic endothelium and simulating the process of restenosis caused by endothelial repair and neointimal proliferation after PCI postoperative vascular endothelial injury; and at the same time, by culturing VSMC and stimulating VSMC proliferation, molecular biology experiment technologies such as siRNA, Western Blot and RT-PCR are applied, the effects and mechanisms of a Notch signal transduction pathway, an inflammatory mediator and a plurality of other signal pathways in inhibition of neointima formation by an ACE2-Ang (l-7)-Mas axis are discussed; the action mechanism of an angiotensin II receptor antagonist ARB drug in prevention of restenosis is studied; and a new theoretical basis and an action target are provided for preventing ISR.

The invention discloses an anticoagulation and rapid endothelialization coating for a degradable plugging device and a preparation method of the anticoagulation and rapid endothelialization coating, relates to the technical field of biomedical engineering functional materials, and provides the anticoagulation and rapid endothelialization coating for the degradable plugging device. Comprising a polymer A with an anticoagulation function, a functional substance B with an endothelial repair promoting function and a hydroxyl functional group capable of degrading surface modification of the plugging device, and the polymer A and the functional substance B are coupled through a cross-linking agent and can be connected with the hydroxyl functional group. In the preparation process, the degradable plugging device body material is treated by plasma or a strong oxidant, and the surface of the obtained hydroxyl functional group provides a site for effective physical and chemical crosslinking between the surface of the obtained hydroxyl functional group and a chemical group of a polymer A in the follow-up process. Through chemical crosslinking between the anticoagulation module and the endothelium promoting compound module, an endothelium promoting compound can be effectively introduced on the premise that the anticoagulation function is guaranteed, and rapid repair after the plugging device is implanted is achieved.

The invention relates to application of a drug in preparation of a drug for treating myocardial ischemia of a coronary heart disease. The drug is prepared from the following crude drugs in parts by weight: 8-12 parts of radix curcumae, 13-17 parts of codonopsis pilosula, and 8-12 parts of radix polygonati officinalis. The application of the drug has the advantages that the drug disclosed by the invention is prepared from pure traditional Chinese medicines, and is wide in symptomatic range, and free of toxic and side effects. The drug disclosed by the invention is fewer in raw components, abundant and available in raw materials, low in price, simple in preparation technology and suitable for promotion and use. The traditional Chinese medicine disclosed by the invention has the functions of expanding coronary artery, resisting platelet aggregation and thrombogenesis, reducing blood viscosity, improving the microcirculation function and promoting angiogenesis and endothelial repair, and is short in course of treatment of myocardial ischemia and significant in effect.

The invention relates to medicine for treatment coronary atherosclerotic heart disease myocardial ischemia. The medicine is prepared from the following crude drugs in parts by weight: 8-12 parts of curcuma aromatica, 13-17 parts of codonopsis pilosula and 8-12 parts of radix polygonati officinalis. The invention has the advantages that the medicine is made from pure traditional Chinese medicine, and wide in symptomatic range, and has no toxic and side effects. The raw material components of the medicine are few, the raw materials are rich and easy to obtain, the price is low, the preparation process is simple, and the medicine is suitable for popularization and application. The medicine has the functions of coronary artery ectasia, anti-platelet aggregation, anti-thrombosis, blood viscosity reduction, microcirculation improvement, angiogenesis promotion and endothelial repair, and is short in course of treatment of the myocardial ischemia, and significant in effect.